Bortezomib from India: why the cost advantage is structural, not a discount.

Bortezomib has been off-patent across the relevant markets for long enough that the generic conversation is no longer about whether to use a generic — it is about which generic, from where, at what price, with what documentation. For a procurement panel comparing a European-origin generic against an Indian WHO-GMP line, the economics, the quality evidence and the operational reality of switching are the three things worth getting right before the tender closes.

Why Indian bortezomib is structurally cheaper.

The cost gap between Indian-origin and European-origin generic bortezomib is not an artefact of one supplier discounting to win a tender. It sits on four foundations, each of which would take a decade to replicate elsewhere.

API concentration. India is home to the largest concentrated base of active pharmaceutical ingredient manufacturing outside China. Bortezomib API is produced at scale by multiple Indian manufacturers, several of whom hold both WHO-GMP and EU-GMP capability. When the API is sourced domestically rather than imported, the finished-dose maker saves on landed cost, on foreign-exchange exposure, and on the regulatory overhead of dual-country traceability.

Skilled labour cost. A Qualified Person, a QC analyst or a sterile-fill operator in India earns roughly 20-30% of the equivalent role in Western Europe on a like-for-like basis. For a labour-intensive process like sterile lyophilised injection manufacture, where multiple hands touch each batch from formulation through vial-fill, that differential compounds.

Installed capacity and capital cost. Sterile fill-finish capex is globally priced — a washer, a filler, a lyophiliser costs what it costs. Operating cost and capacity utilisation are where Indian plants pull ahead. Many of the lines running bortezomib today are depreciated, running high utilisation, with marginal cost of an additional batch well below a new Western facility.

Currency parity. The rupee's position against the dollar, euro and pound has translated through to FOB pricing for long enough that this is no longer volatility — it is a structural input to the finished price.

The order-of-magnitude gap, without the fake precision.

We are going to be deliberately vague about per-vial numbers, and we are going to be vague on purpose. Bortezomib prices move with tender volume, packaging format, destination regulatory route, Incoterm and the specific batch availability. Quoting a single GBP or USD figure for a vial misleads more than it informs.

What we can say, from watching these tenders over several years:

• Indian finished-dose bortezomib, ex-factory FOB Mumbai, typically runs 30-50% below a comparable European-origin generic on a like-for-like 3.5mg vial basis.
• The gap narrows for low-volume named-patient orders, where packaging, dossier and cold-chain fixed costs dominate.
• The gap widens for high-volume tender awards, where the manufacturing cost ratio dominates over fixed costs.

A procurement panel that translates a 30-50% FOB differential through to landed cost, after freight, insurance, regulatory fees and local margin, typically sees a delivered-to-pharmacy cost advantage in the 20-40% range. On a hospital bortezomib budget, for a disease area where multiple myeloma incidence is rising and cycle counts per patient are substantial, that is not a rounding error.

Source the price from the candidate supplier, not from a blog post. But go into the conversation knowing the shape of the gap.

What WHO-GMP bortezomib quality actually looks like.

The legitimate procurement question is not whether Indian bortezomib is cheaper. It is whether the quality evidence holds up against the clinical and regulatory demands of your market. For WHO-GMP-sourced bortezomib, the pack that travels with a consignment looks like this.

Manufacturing credentials

• WHO-GMP certificate for the named manufacturing site, issued by the State Licensing Authority and referenced by CDSCO.
• CDSCO-issued Certificate of Pharmaceutical Product (CoPP) for the specific product, strength and pack.
• Manufacturing licence, Free Sale Certificate, Certificate of Origin from an accredited chamber of commerce.
• For markets that demand it: EU-GMP certificate at the partner site, with the site inspection report available to the importing authority on request.

Batch-level quality evidence

• Batch-specific Certificate of Analysis with HPLC assay, related substances, water content, residual solvents (per ICH Q3C), elemental impurities (per ICH Q3D), sterility and endotoxin.
• Impurity profile identified and quantified under ICH Q3A and Q3B — not simply an assay result, but the full impurity table against specification.
• Lyophilisation cycle validation data, reconstitution-stability summary (reconstituted bortezomib is stable for a short, defined window — the batch-level data should match the innovator reference).
• Method of Analysis, signed by the manufacturer's authorised QC head.

Handling and packaging

Bortezomib is handled under oncology-drug handling procedures. It is not vesicant in the paclitaxel sense, but closed-system transfer devices are standard in pharmacy reconstitution. The finished-dose pack ships under 2-8°C where the manufacturer's stability data requires it, with pre-shipment thermal validation and continuous in-transit temperature logging.

If a procurement panel asks for any of the above and does not receive it within one working day, the file is not ready — irrespective of how attractive the price looks.

Is it the same drug? The biosimilar confusion.

A procurement question we hear periodically is whether Indian bortezomib is a biosimilar of the originator Velcade. The short answer is no — because there is no biosimilar bortezomib. The correct term is bortezomib generic.

Bortezomib is a small-molecule boronate proteasome inhibitor. It is manufactured by defined chemical synthesis and characterised to the full analytical depth small molecules allow — structure confirmed by NMR, mass spectrometry, HPLC purity profile, full impurity identification and quantification. A generic bortezomib is the same molecule as the innovator, and regulators demonstrate this through standard bioequivalence work.

Biosimilars are a separate regulatory category applied to large, structurally complex biological molecules — monoclonal antibodies, fusion proteins, erythropoietins — where the manufacturing process itself is part of the product identity and where a separate clinical comparability package is needed. That category does not apply to bortezomib.

For the procurement panel, the practical consequence is that Indian generic bortezomib must demonstrate pharmacokinetic bioequivalence to the reference innovator — standard PK parameters (Cmax, AUC) within the defined ranges that the EMA, MHRA, SFDA and comparable bodies accept. Multiple Indian generic bortezomib SKUs have cleared this threshold and hold marketing authorisations in regulated markets on this basis.

If you see a supplier's literature describing their bortezomib as a biosimilar, that is a terminology error worth flagging — it does not reflect the regulatory reality of the molecule.

Switching suppliers mid-tender: what breaks, what doesn't.

Procurement leads considering a switch from a European-origin generic to an Indian WHO-GMP line, mid-tender or at renewal, need an honest picture of what changes and what does not.

What breaks

1. Batch-variation on first receipt. A new supplier's first batch may show a slightly different impurity profile, all within specification but distinguishable from the previous supplier's profile. If your hospital's reconstitution SOP references specific lot numbers or supplier-specific process residuals, that SOP needs a documented update.
2. Pack variation. Reconstitution instructions, diluent volume, handling notes and carton artwork will differ. Pharmacy SOPs need updating and staff need briefing before the first dispensed dose.
3. Artwork and labelling. Destination-language pack inserts, regulator-approved phraseology and product-specific regulatory data fields all need sign-off locally before the first consignment can be released to dispensing.
4. Pharmacovigilance continuity. Adverse events reported under the previous supplier's marketing authorisation do not automatically transfer. The incoming supplier opens a separate pharmacovigilance stream, with a nominated local contact and periodic safety update reporting to the destination authority.

What does not break

The clinical profile of the drug, assuming the incoming generic is properly bioequivalent at the same strength. The administration route. The nursing procedure at chair-side. The oncology protocol. The dose per cycle. The infusion pharmacy workflow upstream of reconstitution. These stay exactly as they were.

A procurement panel managing a well-planned switch typically budgets six to eight weeks between award and first dispensed dose — long enough to update pharmacy SOPs, brief clinical staff, clear the first consignment through quality review, and run a controlled starting period. Shorter than that is possible, but starts to eat into the margin for error.

The bortezomib-specific cross-link: for the molecule-level detail on strengths, pack formats and documentation that ships with a consignment, see the bortezomib injection supplier page.

Why the advantage is structural, not transient.

A common procurement concern is whether the Indian cost advantage is about to compress or disappear. A ten-year view suggests not. There are four reasons the gap is structural.

1. API concentration cannot be replicated quickly. Building a new API cluster elsewhere takes a decade-plus and requires cluster effects — supplier ecosystems, skilled labour pools, regulator relationships. No jurisdiction outside India and China has those cluster effects at the scale of small-molecule oncology APIs, and none is close.
2. Installed sterile fill-finish capacity. India's sterile injectable capacity is among the largest globally. Depreciated plants run at high utilisation with low marginal cost per batch. A Western facility, built new, carries both the capex amortisation and the higher operating-cost base from day one.
3. Stable regulatory institutions. WHO-GMP, CDSCO, and the State Licensing Authorities are mature, stable institutions. EU-GMP-capable partner sites exist at scale in India, inspected periodically by European national authorities. The regulatory footing is not fragile.
4. Labour economics. Pharma labour costs in India will rise through the 2020s, but the gap to Western European pharma labour is wide enough that even meaningful rupee-wage inflation leaves a substantial differential in place.

Net effect: the gap will likely compress modestly over the decade — perhaps from a 30-50% FOB differential toward a 25-40% differential — but it will not disappear. For a procurement panel building a 2-5 year tender commitment, the Indian cost advantage is a fact to plan around, not a window that may close.

FAQ

Is Indian generic bortezomib approved in the UK, the EU and the GCC?

Yes. Multiple Indian generic bortezomib SKUs hold marketing authorisations with the MHRA, with EU national authorities, with the SFDA in Saudi Arabia, with MOHAP in the UAE, and with comparable regulators across the GCC and Africa. The approval pathway is the standard small-molecule generic route, demonstrating pharmacokinetic bioequivalence to the innovator reference. A specific SKU's approval status per market is a supplier-level check, not a product-level one — ask for the destination-market marketing authorisation number.

What is the difference between bortezomib biosimilar and bortezomib generic?

There is no bortezomib biosimilar — the term is a category error when applied to this molecule. Bortezomib is a small-molecule boronate proteasome inhibitor, manufactured by defined chemical synthesis. The correct regulatory category is bortezomib generic. Biosimilars apply to large biological molecules (monoclonal antibodies, fusion proteins, erythropoietins) where the manufacturing process itself is part of product identity. For bortezomib, the generic approval pathway — demonstrating PK bioequivalence to the innovator — is the applicable framework.

How should a procurement panel verify quality before awarding a bortezomib tender?

Request, at minimum: WHO-GMP certificate of the named manufacturing site, CDSCO-issued CoPP, destination-market marketing authorisation number, specimen batch Certificate of Analysis with the full impurity profile (not just assay), stability data summary, reconstitution-stability data, pack insert and artwork in the destination-regulator-approved format, and the pharmacovigilance contact for the destination market. If any of the above takes more than one working day to produce, the file is not ready. A good starting frame is the WHO-GMP and CDSCO documentation chain.

What are the realistic lead times and supply commitments for Indian bortezomib tenders?

For a 2-5 year tender commitment, Indian WHO-GMP lines typically commit to a defined monthly or quarterly volume envelope, with 6-10 weeks from confirmed order to dispatch for made-to-order batches, and 5-10 working days where stock is on hand. Air-freight cold-chain transit to the UK or the GCC adds 3-5 days; sea-freight to African destinations adds 18-28 days. Volume commitments beyond the tender floor can be negotiated against firm forward orders with agreed price mechanisms.